Search
16-Bromoepiandrosterone
go.drugbank.com/drugs/DB05107Investigational16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide.
Molnupiravir
go.drugbank.com/drugs/DB15661Investigational[A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to
Boldenone
go.drugbank.com/drugs/DB01541ExperimentalIllicitVet approvedBoldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.
Rexlemestrocel-L
go.drugbank.com/drugs/DB17606InvestigationalRexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product.
CX-2009
go.drugbank.com/drugs/DB16090InvestigationalCX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
Ralmitaront
go.drugbank.com/drugs/DB19128InvestigationalRalmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or
Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum to...
Products: BOTOX®200 U, SIAX ® 50 UElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is market...
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relativ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential